<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35282780</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2374-4243</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Infectious diseases (London, England)</Title><ISOAbbreviation>Infect Dis (Lond)</ISOAbbreviation></Journal><ArticleTitle>Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research.</ArticleTitle><Pagination><StartPage>467</StartPage><EndPage>477</EndPage><MedlinePgn>467-477</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/23744235.2022.2043560</ELocationID><Abstract><AbstractText Label="BACKGROUND">A considerable proportion of individuals report persistent, debilitating and disparate symptoms despite resolution of acute COVID-19 infection (i.e. long COVID). Numerous registered clinical trials investigating treatment of long COVID are expected to be completed in 2021-2022. The aim of this review is to provide a scope of the candidate treatments for long COVID. A synthesis of ongoing long COVID clinical trials can inform methodologic approaches for future studies and identify key research vistas.</AbstractText><AbstractText Label="METHODS">Scoping searches were conducted on multiple national and international clinical trial registries. Interventional trials testing treatments for long COVID were selected. The search timeline was from database inception to 28 July 2021.</AbstractText><AbstractText Label="RESULTS">This scoping review included 59 clinical trial registration records from 22 countries with a total projected enrolment of 6718. Considerable heterogeneity was exhibited amongst component records with respect to the characterization of long COVID (i.e. name, symptoms- including frequency, intensity, trajectory and duration- mode of ascertainment, and definition of acute phase). In addition, the majority of proposed interventions were non-pharmacological and either targeted multiple long COVID symptoms simultaneously, or focussed on treatment of respiratory/pulmonary sequelae. Multiple interventions targeted inflammation, as well as tissue oxygenation and cellular recovery, and several interventions were repurposed from analogous conditions.</AbstractText><AbstractText Label="CONCLUSIONS">The results of this scoping review investigating ongoing clinical trials testing candidate treatments for long COVID suggest that a greater degree of definitional stringency and homogeneity is needed insofar as the characterization of long COVID and inclusion/exclusion criteria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceban</LastName><ForeName>Felicia</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6815-7248</Identifier><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leber</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawad</LastName><ForeName>Muhammad Youshay</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lui</LastName><ForeName>Leanna M W</ForeName><Initials>LMW</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniapillai</LastName><ForeName>Mehala</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Vincenzo</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Hartej</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Nelson B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Bing</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5963-2676</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yena</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Kangguang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Affective Disorders, the Affiliated Brain Hospital of Guangzhou Medical University, (Guangzhou Huiai Hospital), Guangzhou Medical University, Guangzhou, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Emotion and Cognition, the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou Medical University, Guangzhou, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansur</LastName><ForeName>Rodrigo B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenblat</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Infect Dis (Lond)</MedlineTA><NlmUniqueID>101650235</NlmUniqueID><ISSNLinking>2374-4243</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">dyspnoea</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">post-COVID-19 condition</Keyword><Keyword MajorTopicYN="N">rehabilitation</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>FC and RSM conceptualized and designed study. FC and AL performed study search and selection. FC, AL, MYJ and MY performed data extraction. FC and AL performed data synthesis. FC performed data analyses and drafted the manuscript. All authors revised and approved the final version of the manuscript. RSM has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. RSM is a CEO of Braxia Scientific Corp. JDR is the medical director of Braxia Health (formally known as the Canadian Rapid Treatment Centre of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck and Sunovion. YL has received personal fees from Braxia Scientific Corp. LMWL has received personal fees from Braxia Scientific Corp and honoraria Medscape. All other authors declare no conflicts of interest or financial disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>14</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35282780</ArticleId><ArticleId IdType="pmc">PMC8935463</ArticleId><ArticleId IdType="doi">10.1080/23744235.2022.2043560</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. . More than 50 long-term effects of COVID-19: a systematic review and Meta-analysis. Sci Rep. 2021;11(1):16144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Cheng V, Manoharan L, et al.  Characterising long term Covid-19: a living systematic review. bioRxiv. 2020. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.12.08.20246025</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.08.20246025</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021. DOI:10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC . Post-COVID conditions. 2021. [cited 2021 Jul 22]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html</Citation></Reference><Reference><Citation>NIH launches new initiative to study &#x201c;long COVID.&#x201d; 
2021.  [cited 2021 Sep 2]. Available from: https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid</Citation></Reference><Reference><Citation>Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance | NICE. 2021 [cited 2021 May 19]. Available from: https://www.nice.org.uk/guidance/ng188</Citation></Reference><Reference><Citation>Report: what does COVID-19 recovery actually look like? - patient led research collaborative. 2020.  [cited 2021 Aug 26]. Available from: https://patientresearchcovid19.com/research/report-1/</Citation></Reference><Reference><Citation>Havers FP, Reed C, Lim T, et al. . Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, march 23-may 12, 2020. JAMA Intern Med. 2020;180(12):1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">32692365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SL, Mertens AN, Crider YS, et al. . Substantial underestimation of SARS-CoV-2 infection in the United States. Nat Commun. 2020;11(1):4507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481226</ArticleId><ArticleId IdType="pubmed">32908126</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenman N. Why the pandemic is 10 times worse than you think. NPR. 2021.  [cited 2021 May 19]. Available from: https://www.npr.org/sections/health-shots/2021/02/06/964527835/why-the-pandemic-is-10-times-worse-than-you-think</Citation></Reference><Reference><Citation>Xiong J, Lipsitz O, Nasri F, et al. . Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020; 277:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7413844</ArticleId><ArticleId IdType="pubmed">32799105</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;Bad brain fog&#x201d;: patients who had covid-19 reveal new phenomenon - CNN Video. CNN. 2021.  [cited 2021 Jul 22]. Available from: https://www.cnn.com/videos/health/2021/02/19/post-covid-symptoms-gupta-vpx.cnn</Citation></Reference><Reference><Citation>Chapter 11: Scoping reviews. 2020 [cited 2021 Aug 25]. Available from: https://wiki.jbi.global/display/MANUAL/Chapter + 11%3A+Scoping+reviews</Citation></Reference><Reference><Citation>Peyrovian B, McIntyre RS, Phan L, et al. . Registered clinical trials investigating ketamine for psychiatric disorders. J Psychiatr Res. 2020;127:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">32315806</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel AN, Meshkat S, Benitah K, et al. . Registered clinical studies investigating psychedelic drugs for psychiatric disorders. J Psychiatr Res. 2021; 139:71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">34048997</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricco AC, Lillie E, Zarin W, et al. . PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">30178033</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan F, Gelman JS, Ditchman N, et al. . The world health organization ICF model as a conceptual framework of disability. In: Chan F, editor. Understanding psychosocial adjustment to chronic illness and disability: a handbook for evidence-based practitioners in rehabilitation. New York (NY): Springer Publishing Co.; 2009. p. 23&#x2013;50.</Citation></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman LA, Vilensky JA.. Encephalitis lethargica: 100 years after the epidemic. Brain. 2017;140(8):2246&#x2013;2251.</Citation><ArticleIdList><ArticleId IdType="pubmed">28899018</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrousos GP, Kaltsas G.. Post-SARS sickness syndrome manifestations and endocrinopathy: how, why, and so what? Clin Endocrinol (Oxf). 2005;63(4):363&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162060</ArticleId><ArticleId IdType="pubmed">16181227</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky H, Patcai J.. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ho RCM, Mak A.. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-&#x3b1;) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a Meta-analysis and Meta-regression. J Affect Disord. 2012;139(3):230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">21872339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng A, Tam WW, Zhang MW, et al. . IL-1&#x3b2;, IL-6, TNF- &#x3b1; and CRP in elderly patients with depression or Alzheimer&#x2019;s disease: systematic review and meta-analysis. Sci Rep. 2018;8(1):12050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6089986</ArticleId><ArticleId IdType="pubmed">30104698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Mansur RB, Brietzke E, et al. . Peripheral inflammatory biomarkers define biotypes of bipolar depression. Mol Psychiatry. 2021;26(7):3395&#x2013;3406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413393</ArticleId><ArticleId IdType="pubmed">33658605</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke MJ, Del Rio C.. Long COVID has exposed medicine&#x2019;s blind-spot. Lancet Infect Dis. 2021;21(8):1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213360</ArticleId><ArticleId IdType="pubmed">34153235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho RC, Sharma VK, Tan BYQ, et al. . Comparison of brain activation patterns during olfactory stimuli between recovered COVID-19 patients and healthy controls: a functional near-Infrared spectroscopy (fNIRS) study. Brain Sci. 2021;11(8):968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391911</ArticleId><ArticleId IdType="pubmed">34439587</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Ho CS, Liu X, et al. . Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression. PLoS One. 2017;12(10):e0186700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648231</ArticleId><ArticleId IdType="pubmed">29049348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MWB, Ho RCM.. Moodle: the cost effective solution for internet cognitive behavioral therapy (I-CBT) interventions. Technol Health Care. 2017;25(1):163&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">27689560</ArticleId></ArticleIdList></Reference><Reference><Citation>Soh HL, Ho RC, Ho CS, et al. . Efficacy of digital cognitive behavioural therapy for insomnia: a meta-analysis of randomised controlled trials. Sleep Med. 2020;75:315&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">32950013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TL, Weitzer DJ.. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina. 2021;57(5):418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Munblit D, De Rose C, et al. . Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110(7):2208&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251440</ArticleId><ArticleId IdType="pubmed">33835507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Nogo D, Carvalho IP, et al. . Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and Meta-analysis. JAMA Psychiatry. 2021;78(10):1079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319830</ArticleId><ArticleId IdType="pubmed">34319365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>